Amgen and MediLink Therapeutics have agreed to a research and supply collaboration to develop a combination therapy for extensive-stage small cell lung cancer (ES-SCLC). Suzhou, China-based biotech ...
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; ...
MediLink Therapeutics Ltd. is exploring a licensing partnership to develop an antibody-drug conjugate with a global pharmaceutical company, according to people familiar with the situation. MediLink is ...
The FDA has lifted the partial clinical hold on MediLink Therapeutics’ Phase 1 trial for BNT326/YL202, a HER3-targeting antibody-drug conjugate (ADC). This decision, announced on August 15, follows ...
Roche has got in on the B7-H3 action, agreeing to $570 million in near-term payments to existing partner MediLink Therapeutics for an antibody-drug conjugate targeting the immune checkpoint protein.
SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, ...
SUZHOU, China, May 26, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic ...
The FDA has allowed MediLink Therapeutics to restart a phase 1 trial of its BioNTech-partnered antibody-drug conjugate (ADC) that saw three fatalities after the companies confirmed that only lower ...
SHANGHAI--(BUSINESS WIRE)--Pacific Prime, a leading intermediary of international health insurance and employee benefits solutions, is proud to announce that it has been honored with the prestigious ...
SAN ANTONIO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for an antibody drug conjugate (ADC) that shows ...
The decision follows complete response data, including data analysis, updated documentation, and additional risk mitigation measures. The FDA hold stemmed from concerns over dose-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results